ClinicalTrials.gg
RecruitingNCT07645222Updated Jul 6, 2026

PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC

A Phase 1 interventional study of HS-20122+Aumolertinib and HS-20122+Adbrelimab in Lung Cancer, sponsored by Hansoh BioMedical R&D Company. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
396
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing aumolertinib in Lung Neoplasms — 3 open to participants now, 5 under way, 2 of them phase 3. aumolertinib · Lung Neoplasms.

Planned enrollment
Largest of 10
396 · median 40
Started
2026
the only one that year
Phase 1
Only one
of the 10
Registered
11th of 10
by date

Among the 10 studies testing aumolertinib in Lung Neoplasms, this one has the largest planned enrollment, is the only one that started in 2026, is the only one in phase 1, and was the 11th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

3 of the 10 studies testing aumolertinib in Lung Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About aumolertinib

aumolertinib: first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing aumolertinib in Lung Neoplasms, or all of them as a file.
02

Study summary

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Read the detailed description

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combination therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC). A dose exploration stage of each combination therapy will be conducted in subjects with advanced or metastatic NSCLC patients who experienced disease progression (PD) on or after prior treatments, to explore appropriate doses. In addition, an dose-expansion stage will be conducted in appropriate target populations based on the data obtained in the dose exploration stage to further explore the safe and efficacy.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Lung cancer
  • Tyrosine Kinase Inhibitor
  • Immuno-Checkpoint Inhibitor
  • Antibody Drug Conjugate
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Locally advanced or metastastic NSCLC;
  2. Received at least 1 line SoC,or treatment naïve;
  3. With at least 1 target lesion according to 1.1.
  4. Appropriate organ function
  5. (ECOG) performance status (PS) score of 0-1 and no deterioration within 2 weeks prior to the first dose.
  6. Minimum expected survival longer than 12 weeks
  7. Female subjects of are willing to take appropriate measures and should not breastfeed from signing the form (ICF) through 6 months after the last dose; male subjects are willing to use barrier contraception (i.e., condom) from signing the ICF through 6 months after the last dose.
  8. Voluntarily participate in this clinical trial, understand the study procedures, and be able to sign written informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Insufficient wash out duration of prior systemic anticancer therapy
  2. Local radiotherapy within 2 weeks prior to first dose of drug
  3. Pleural/abdominal effusion requires clinical intervention
  4. Major surgery within 4 weeks prior to first dose of investigational drug
  5. History of drugs may prolong
  6. Have any grade ≥ 2 residual toxicity according to (CTCAE, version 5.0) from prior anti-tumor therapy (except alopecia and residual neurotoxicity).
  7. Presence of or carcinomatous meningtitis
  8. History of other primary
  9. Significant, uncontrolled, or active cardiovascular diseases
  10. Severe or poorly controlled diabetes
  11. Extremely obesity or emaciation
  12. bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose
  13. Severe arteriovenous thrombotic events (e.g., deep venous thrombosis, pulmonary embolism) within 3 months prior to the first dose
  14. Severe infection within 4 weeks
  15. History of systemic over 28 days prior to first dose of investigational drug
  16. Presence of known active infectious diseases,
  17. Prensence of ophthalmological abnormalities.

17.Presence of hepatic encephalopathy, Hepato-renal Syndrome 18.Presence or history of confirmed or suspected ILD; 19.Prior history of significant neurological or mental disorders, including conditions that interfere with assessment, such as epilepsy, dementia, or major depressive disorder.

20.History of severe allergy, or history of to any active or inactive ingredient of investigational drugs.

21.Presence of any conditions that jeopardize subject safety or interfere with study assessments as judged by the investigator.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
396 participants (estimated)

Study arms

  • Experimental
    HS-20122+Aumolertinib

    Drug: HS-20122+Aumolertinib

  • Experimental
    HS-20122+Adbrelimab

    Drug: HS-20122+Adbrelimab

  • Experimental
    HS-20122+Adbrelimab+Platinum-based Chemo

    Drug: HS-20122+Adbrelimab+Platinum-based Chemo

Interventions

  • DrugHS-20122+Aumolertinib

    Drug page: Aumolertinib

    EGFR mut NSCLC, receive HS-20122+Aumolertinib

  • DrugHS-20122+Adbrelimab

    EGFRwt NSCLC,receive HS-20122+Adbrelimab

  • DrugHS-20122+Adbrelimab+Platinum-based Chemo

    EGFR wt NSCLC,receive HS-20122+Adbrelimab+ Platinum-based Chemo

06

What researchers measure

Primary outcomes

  1. RP2D for Combination

    To evaluate the potent and tolerated of combination(s) and dosage(s) of HS-20122 based therapy in subjects with locally advanced or metastatic NSCLC who have experienced disease progression on or after prior treatment, which suitable for a Phase II trial

    Time frame: Through the full duration of this trial, approximately 2 years

  2. ORR

    Investigator evaluated overall response rate, to evaluate the efficacy of each combination;

    Time frame: Through the full duration of this trial, approximately 2 years;

  3. TEAE

    incidence of Investigator evaluated Treatment Emerged Adverse Events, graded per CTCAE V5.0

    Time frame: Through the full duration of this trial, approximately 2 years;

  4. TRAE

    incidence of Investigator evaluated Treatment Related Adverse Events, graded per CTCAE V5.0

    Time frame: Through the full duration of this trial, approximately 2 years;

  5. SAE

    incidence of Investigator evaluated Severe Adverse Events, graded per CTCAE V5.0

    Time frame: Through the full duration of this trial, approximately 2 years

Secondary outcomes

  1. Duration of Response

    Investigator evaluated Duration of Response

    Time frame: Through the full duration of this trial ,approximately 2 years

  2. Disease Control Rate

    Investigator evaluated Disease Control Rate

    Time frame: Through the full duration of this trial ,approximately 2 years;

  3. Progression Free Survival

    Investigator evaluated duration of Progression Free Survival

    Time frame: Through the full duration of this trial, approximately 2 years;

  4. Overall Survival

    Investigator evaluated duration of Overall Survival

    Time frame: Through the full duration of this trial ,approximately 2 years;

  5. PK parameter

    blood concentration of combo agents

    Time frame: Through the full duration of this trial, approximately 2 years;

  6. Immuogencity

    positive rate of drug specific antibody

    Time frame: Through the full duration of this trial ,approximately 2 years;

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Oct 2028, 28 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 28 months is below that.

Counting every sponsor, half of 291 studies reached it within 52 months; a quarter within 28 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 12, 2026
StartActual
Jun 15, 2026
Primary completionEst.
Oct 31, 2028
CompletionEst.
Apr 30, 2029
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07645222
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Jun 15, 2026
Primary completion
Oct 31, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Jul 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aumolertinib

Start the discussion